BRCA2 mutation

Castration-Resistant Prostate Carcinoma

Predictive

Supports Sensitivity Response

accepted

EID8842

In phase 3 trial of 387 patients comparing olaparib and new hormonal agent (enzalutamide or abiraterone) therapy for patients with metastatic castration-resistant prostate cancer harboring homologous … (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

Malignant Breast Neoplasm

〃

Predictive

Supports Sensitivity Response

accepted

EID5831

Randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation HER2–negative metastatic breast cancer. 205 patients we… (full text at CIViC)

PMID 28792849 · 2017 · Open in CIViC

〃

Malignant NeoplasmALIAS

Predictive

Supports Sensitivity Response

accepted

EID1371

In this phase 1 trial 60 patients with advanced solid tumors (ovarian, breast, colorectal, melanoma, sarcoma, prostate) were treated with PARP inhibitor olaparib. Durable antitumor activity was only o… (full text at CIViC)

PMID 19553641 · Fong et al., 2009 · Open in CIViC

〃

Predictive

Supports Sensitivity Response

accepted

EID7276

In the phase 3 SOLO1 trial 390 patients with newly diagnosed advanced ovarian cancer with a mutation in BRCA1 or BRCA2 who had complete or partial response after platinum-based chemotherapy were rando… (full text at CIViC)

PMID 30345884 · Moore et al., 2018 · Open in CIViC

〃

Predictive

Supports Sensitivity Response

accepted

EID1773

In a study of 63 patients with ovarian cancer, 17 patients had BRCA1 or BRCA2 mutations and 46 patients had no BRCA mutations. Of the BRCA-positive patients, 7/17(41%; 95%CI 22-64) showed objective r… (full text at CIViC)

PMID 21862407 · Gelmon et al., 2011 · Open in CIViC

Cediranib + OlaparibCombination

Predictive

Supports Sensitivity Response

accepted

EID1678

46 women with platinum-sensitive, high-grade, BRCA1/2+ ovarian cancer received either olaparib monotherapy or olaparib/cediranib combination therapy. Median PFS was increased in combination therapy (… (full text at CIViC)

PMID 25218906 · Liu et al., 2014 · Open in CIViC

Predictive

Supports Sensitivity Response

accepted

EID11137

Combined meta-analysis of Study 10 (NCT01482715, phase I/II) and ARIEL2 (NCT01891344, phase II), both multi-centre, open-label, single-arm trials evaluating rucaparib in ovarian cancer with BRCA1 or B… (full text at CIViC)

PMID 28882436 · Oza et al., 2017 · Open in CIViC

〃

Predictive

Supports Sensitivity Response

accepted

EID11139

PMID 28882436 · Oza et al., 2017 · Open in CIViC

〃

Predictive

Supports Sensitivity Response

accepted

EID2868

A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib… (full text at CIViC)

PMID 27908594 · Swisher et al., 2017 · Open in CIViC

〃

Predictive

Supports Sensitivity Response

accepted

EID6343

PMID 27908594 · Swisher et al., 2017 · Open in CIViC

Iniparib

Predictive

Supports Sensitivity Response

accepted

EID5936

Patient with germline BRCA2 mutation underwent resection of pancreatic cancer. Around three years later, tumor recurrence was detected by MRI and PET-CT confirmed it. She was treated with gemcitabine … (full text at CIViC)

PMID 21508395 · Fogelman et al., 2011 · Open in CIViC

Predictive

Supports Sensitivity Response

accepted

EID5913

Twenty-three patients with pancreatic cancer havoring BRCA1/2 germline mutations received olaparib. Eighteen (78%) patients had a BRCA2 mutation. In total of patients with BRCA1/2 mutation , all but … (full text at CIViC)

PMID 25366685 · Kaufman et al., 2015 · Open in CIViC

Platinum Compound

Predictive

Supports Sensitivity Response

accepted

EID5916

Patients with BRCA1/2 associated pancreatic adenocarcinoma were evaluated retrospectively. In patients with stage 3 and 4, the median overall survival (mOS) was 22 months for the platinum exposed (n=2… (full text at CIViC)

PMID 25072261 · Golan et al., 2014 · Open in CIViC

Veliparib

Predictive

Does Not Support Sensitivity Response

accepted

EID5935

Veliparib 400mg bid was administered to patients with germline BRCA1/2 mutated pancreatic cancer. Sixteen pts was enrolled. All except two pts (12.5%) had previously been treated with platinum therapy… (full text at CIViC)

PMID 29223478 · Lowery et al., 2018 · Open in CIViC

Cisplatin + Gemcitabine + VeliparibCombination

Predictive

Supports Sensitivity Response

accepted

EID5933

In Phase I study for pancreatic cancer patients GEM 600 mg/m2 + CDDP 25 mg/m2 + Veliparib 20 - 80 mg twice daily showed response rate of 77.8% (7/9) and mOS of 23.3 months in germline BRCA mutation-p… (full text at CIViC)

PMID 29338080 · O'Reilly et al., 2018 · Open in CIViC

Platinum Compound

Ovarian Carcinoma

Predictive

Supports Sensitivity Response

accepted

EID1530

In a study of ovarian carcinomas, 81% of tumors with germline BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=47; N=158; P=0… (full text at CIViC)

PMID 24240112 · Pennington et al., 2014 · Open in CIViC

〃

Ovarian Carcinoma

Predictive

Supports Sensitivity Response

accepted

EID1532

In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=38; N=158; P=0.… (full text at CIViC)

PMID 24240112 · Pennington et al., 2014 · Open in CIViC

Carboplatin + CisplatinSubstitutes

Triple-Negative Breast CarcinomaALIAS

Predictive

Supports Sensitivity Response

accepted

EID1685

In an evaluation of 77 patients, those who had BRCA1/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.0… (full text at CIViC)

PMID 25847936 · Isakoff et al., 2015 · Open in CIViC

Triple-Negative Breast CarcinomaALIAS

Predictive

Does Not Support Sensitivity Response

accepted

EID1776

In a study of 26 patients with breast cancer, 10 patients were BRCA-positive and 16 patients were BRCA-negative. Regardless of BRCA status, none showed objective response when treated with olaparib.

PMID 21862407 · Gelmon et al., 2011 · Open in CIViC

BRCA2 K3326*1
Olaparib + TemozolomideCombination	GlioblastomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	accepted	EID7724 In a case report, a 3‐year‐old girl with glioblastoma harboring a probable germline heterozygous BRCA2 Lys3326Ter (K3326*) nonsense variant. After debulking surgery, the patient received standard‐of‐c… (full text at CIViC) PMID 32043779 · Valiakhmetova et al., 2020 · Open in CIViC	civic

BRCA2 K3326*1

Olaparib + TemozolomideCombination

GlioblastomaCURATED_BROADER

Predictive

Supports Sensitivity Response

accepted

EID7724

In a case report, a 3‐year‐old girl with glioblastoma harboring a probable germline heterozygous BRCA2 Lys3326Ter (K3326*) nonsense variant. After debulking surgery, the patient received standard‐of‐c… (full text at CIViC)

PMID 32043779 · Valiakhmetova et al., 2020 · Open in CIViC

Malignant Breast Neoplasm

BRCA2 Loss-of-function10
Pidnarulex + QuarfloxinSubstitutes	Malignant Breast Neoplasm	Predictive	D	Supports Sensitivity Response	4	accepted	EID1925 The authors show that in the CX-5461 and CX-3543, G-quadruplex stabilizing agents, demonstrate specific toxicity against BRCA deficient breast cancer derived cells and polyclonal patient-derived xenog… (full text at CIViC) PMID 28211448 · Xu et al., 2017 · Open in CIViC	civic
Talazoparib	Malignant Breast Neoplasm	Predictive	B	Supports Sensitivity Response	4	accepted	EID4839 In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment.… (full text at CIViC) PMID 28242752 · de Bono et al., 2017 · Open in CIViC	civic
Olaparib	Malignant Ovarian Neoplasm	Predictive	B	Supports Sensitivity Response	4	accepted	EID212 The combination of PARP inhibition (Olaparib) with BRCA mutation results in irreparable and lethal DNA damage. Response rates are higher in BRCA2 mutation positive women with high grade serous or undi… (full text at CIViC) PMID 23346317 · Goff, 2013 · Open in CIViC	civic
Talazoparib	Malignant Ovarian Neoplasm	Predictive	B	Supports Sensitivity Response	3	accepted	EID4875 In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment.… (full text at CIViC) PMID 28242752 · de Bono et al., 2017 · Open in CIViC	civic
Mitomycin	Malignant Pancreatic Neoplasm	Predictive	D	Supports Sensitivity Response	2	accepted	EID1308 In pancreatic cell lines PL11 (FANCC-deficient) and CAPAN1 (BRCA2-mutated), sensitivity to DNA cross-linking agents was observed compared to FANCC/BRCA2 wildtype cell lines (Su86.86, CFPAC, AsPc1, and… (full text at CIViC) PMID 16243825 · van der Heijden et al., 2005 · Open in CIViC	civic
Olaparib	Malignant Prostate Neoplasm	Predictive	B	Supports Sensitivity Response	4	accepted	EID650 In a phase 2 trial of patients with metastatic, castration-resistant prostate cancer, treated with olaparib tablets at a dose of 400 mg twice a day, all 7 patients harbouring BRCA2 loss of function al… (full text at CIViC) PMID 26510020 · Mateo et al., 2015 · Open in CIViC	civic
〃	Pancreatic Adenocarcinoma	Predictive	A	Supports Sensitivity Response	5	accepted	EID7385 In the phase 3 POLO trial patients who had germline BRCA1/2 mutation and metastatic pancreatic adenocarcinoma that had not progressed during first-line platinum-based chemotherapy were allocated to ma… (full text at CIViC) PMID 31157963 · Golan et al., 2019 · Open in CIViC	civic
〃	Triple-Negative Breast CarcinomaALIAS	Predictive	A	Supports Sensitivity Response	5	accepted	EID11217 Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1… (full text at CIViC) PMID 34081848 · Tutt et al., 2021 · Open in CIViC	civic
〃	HER2 Negative Breast CancerUNRESOLVED	Predictive	A	Supports Sensitivity Response	5	accepted	EID11202 Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1… (full text at CIViC) PMID 34081848 · Tutt et al., 2021 · Open in CIViC	civic
〃	HER2 Negative Breast CancerUNRESOLVED	Predictive	B	Supports Sensitivity Response	3	accepted	EID5816 302 patients (234 with progression events) with HER2-negative metastatic breast cancer and with a confirmed deleterious or suspected deleterious germline BRCA mutation (164 BRCA1, 129 BRCA2) had signi… (full text at CIViC) PMID 28578601 · Robson et al., 2017 · Open in CIViC	civic

BRCA2 Loss-of-function10

Pidnarulex + QuarfloxinSubstitutes

Predictive

Supports Sensitivity Response

accepted

EID1925

The authors show that in the CX-5461 and CX-3543, G-quadruplex stabilizing agents, demonstrate specific toxicity against BRCA deficient breast cancer derived cells and polyclonal patient-derived xenog… (full text at CIViC)

PMID 28211448 · Xu et al., 2017 · Open in CIViC

Malignant Breast Neoplasm

Talazoparib

Predictive

Supports Sensitivity Response

accepted

EID4839

In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment.… (full text at CIViC)

PMID 28242752 · de Bono et al., 2017 · Open in CIViC

Predictive

Supports Sensitivity Response

accepted

EID212

The combination of PARP inhibition (Olaparib) with BRCA mutation results in irreparable and lethal DNA damage. Response rates are higher in BRCA2 mutation positive women with high grade serous or undi… (full text at CIViC)

PMID 23346317 · Goff, 2013 · Open in CIViC

Talazoparib

Predictive

Supports Sensitivity Response

accepted

EID4875

PMID 28242752 · de Bono et al., 2017 · Open in CIViC

Mitomycin

Predictive

Supports Sensitivity Response

accepted

EID1308

In pancreatic cell lines PL11 (FANCC-deficient) and CAPAN1 (BRCA2-mutated), sensitivity to DNA cross-linking agents was observed compared to FANCC/BRCA2 wildtype cell lines (Su86.86, CFPAC, AsPc1, and… (full text at CIViC)

PMID 16243825 · van der Heijden et al., 2005 · Open in CIViC

Malignant Prostate Neoplasm

Predictive

Supports Sensitivity Response

accepted

EID650

In a phase 2 trial of patients with metastatic, castration-resistant prostate cancer, treated with olaparib tablets at a dose of 400 mg twice a day, all 7 patients harbouring BRCA2 loss of function al… (full text at CIViC)

PMID 26510020 · Mateo et al., 2015 · Open in CIViC

Pancreatic Adenocarcinoma

〃

Predictive

Supports Sensitivity Response

accepted

EID7385

In the phase 3 POLO trial patients who had germline BRCA1/2 mutation and metastatic pancreatic adenocarcinoma that had not progressed during first-line platinum-based chemotherapy were allocated to ma… (full text at CIViC)

PMID 31157963 · Golan et al., 2019 · Open in CIViC

〃

Triple-Negative Breast CarcinomaALIAS

Predictive

Supports Sensitivity Response

accepted

EID11217

Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1… (full text at CIViC)

PMID 34081848 · Tutt et al., 2021 · Open in CIViC

〃

HER2 Negative Breast CancerUNRESOLVED

Predictive

Supports Sensitivity Response

accepted

EID11202

PMID 34081848 · Tutt et al., 2021 · Open in CIViC

〃

HER2 Negative Breast CancerUNRESOLVED

Predictive

Supports Sensitivity Response

accepted

EID5816

302 patients (234 with progression events) with HER2-negative metastatic breast cancer and with a confirmed deleterious or suspected deleterious germline BRCA mutation (164 BRCA1, 129 BRCA2) had signi… (full text at CIViC)

PMID 28578601 · Robson et al., 2017 · Open in CIViC

BRCA2 M1R1
Rucaparib	Malignant Ovarian Neoplasm	Predictive	C	Supports Sensitivity Response	—	accepted	EID2879 In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC	civic

BRCA2 M1R1

Predictive

Supports Sensitivity Response

—

accepted

EID2879

In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC)

PMID 27908594 · Swisher et al., 2017 · Open in CIViC

BRCA2 M1?1
Rucaparib	Malignant Ovarian Neoplasm	Predictive	C	Supports Sensitivity Response	—	accepted	EID2880 In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC	civic

BRCA2 M1?1

Predictive

Supports Sensitivity Response

—

accepted

EID2880

PMID 27908594 · Swisher et al., 2017 · Open in CIViC

BRCA2 V159M1
Rucaparib	Malignant Ovarian Neoplasm	Predictive	C	Supports Sensitivity Response	—	accepted	EID2881 In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC	civic

BRCA2 V159M1

Predictive

Supports Sensitivity Response

—

accepted

EID2881

PMID 27908594 · Swisher et al., 2017 · Open in CIViC

BRCA2 V211L1
Rucaparib	Malignant Ovarian Neoplasm	Predictive	C	Supports Sensitivity Response	—	accepted	EID2882 In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC	civic

BRCA2 V211L1

Predictive

Supports Sensitivity Response

—

accepted

EID2882

PMID 27908594 · Swisher et al., 2017 · Open in CIViC

BRCA2 V211I1
Rucaparib	Malignant Ovarian Neoplasm	Predictive	C	Supports Sensitivity Response	4	accepted	EID2883 In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC	civic

BRCA2 V211I1

Predictive

Supports Sensitivity Response

accepted

EID2883

PMID 27908594 · Swisher et al., 2017 · Open in CIViC

BRCA2 R2336P1
Rucaparib	Malignant Ovarian Neoplasm	Predictive	C	Supports Sensitivity Response	—	accepted	EID2884 In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC	civic

BRCA2 R2336P1

Predictive

Supports Sensitivity Response

—

accepted

EID2884

PMID 27908594 · Swisher et al., 2017 · Open in CIViC